Navigation Links
Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
Date:12/1/2008

BASKING RIDGE, N.J., Dec. 1 /PRNewswire/ -- Regado Biosciences, Inc., announced today David J. Mazzo, Ph.D., President and Chief Executive Officer, will present at the 20th Annual Piper Jaffray Health Care Conference in New York, NY, on Tuesday, December 2, 2008, at 10:10am (Eastern Standard Time). Dr. Mazzo will discuss the Company's development pipeline, in addition to reviewing recent business and clinical developments.

About Regado Biosciences

Regado Biosciences is pioneering a new therapeutic field with the creation and development of two-component drug systems, comprising an aptamer therapeutic that can be controlled directly by its specific and matched reversal agent. Regado's technology is designed to give physicians the ability to directly control and titrate each system's therapeutic effect. Enhanced control and flexibility allow physicians to meet the individual needs of patients independent of the setting. Regado is focusing its discovery and development efforts on acute care injectable antithrombotics, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control.

Current investors in Regado include Domain (Princeton, NJ), Quaker BioVentures (Philadelphia, PA), Aurora Funds (Durham, NC) and Caxton Advantage Life Sciences Fund (New York, NY), as well as individual investors, including Robert Kierlin.


'/>"/>
SOURCE Regado Biosciences
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
2. Regado Biosciences REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
3. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
4. Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America
5. Neurocrine Biosciences to Present at the 20th Annual Piper Jaffray Health Care Conference
6. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
7. BBM Announces Offer to Acquire YM BioSciences Inc.
8. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
9. LI-COR Biosciences and Mandel Scientific Company Inc. Announce Distribution Agreement
10. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
11. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , ... October 12, 2017 , ... ... with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of ... trends in analytical testing are being attributed to new regulatory requirements for all ...
(Date:10/11/2017)... Palo Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... is set to take place on 7th and 8th June 2018 in San Francisco, ... and policy influencers as well as several distinguished CEOs, board directors and government officials ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... compared the implantation and pregnancy rates in frozen and fresh in vitro ... of progesterone and maternal age to IVF success. , After comparing the results ...
(Date:10/10/2017)... ... , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on August ... MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
Breaking Biology News(10 mins):